FDA confirms durable pain palliation as an acceptable primary endpoint
for a regulatory submission in support of market approval
BOTHELL, WA, April 28 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ:
OGXI) announced today that the company has reached an agreement with the U.S.
Food and Drug Administration (FDA) on the design of a second Phase 3
registration trial of OGX-011, its lead product candidate targeting castrate
resistant prostate cancer (CRPC), via the Special Protocol Assessment (SPA)
process. The FDA has agreed that the design and planned analysis of our Phase
3 trial featuring durable pain palliation as the primary endpoint adequately
addresses the objectives necessary to support a regulatory submission.
"We have now received confirmations on two separate Phase 3 trial designs
from the FDA via the SPA process, each in second-line treatment of advanced
prostate cancer," said Scott Cormack, President and CEO of OncoGenex
Pharmaceuticals. "One trial design evaluates overall survival benefit while
the second trial design evaluates reduction in pain as the primary endpoint.
Having evaluated both of these endpoints in our Phase 2 trials, we are well
positioned to re-evaluate each of these endpoints in larger Phase 3
"The FDA's acknowledgement of pain in addition to survival as key
endpoints for market approval supports the basis of our OGX-011 development
program for advanced prostate cancer," added Cormack. "Although we observed a
positive effect on PSA in our Phase 2 trials of OGX-011, we recognize that PSA
response has not been shown to correlate to a clinical benefit and therefore
is not an acceptable endpoint for FDA approval. Our focus remains on survival
and pain palliation, both endpoints that FDA has confirmed are appropriate for
marketing approval, and both endpoints for which we have had success in our
Phase 2 clinical trials. Based on the recent survival benefit of combining
OGX-011 with first-line docetaxel chemotherapy, we have initiated discussions
with FDA for evaluating the overall survival benefit in first-line CRPC,
instead of second-line CRPC."
The Phase 3 trial evaluating durable pain palliation has been designed in
collaboration with internationally recognized experts in the treatment of
patients with CRPC (previously referred to as hormone-refractory prostate
cancer) including Dr. Tomasz Beer at the University of Oregon and Dr.
Sebastian Hotte at Juravinski Cancer Centre, in Hamilton, Ontario, Canada.
This will be a randomized, controlled, international trial in approximately
300 men with metastatic CRPC who responded to first-line docetaxel therapy,
but subsequently have progression of disease, including prostate
cancer-related pain, and are able to receive docetaxel retreatment as
second-line chemotherapy. Patients will be randomized to receive treatment
with either OGX-011 and docetaxel/prednisone or docetaxel/prednisone alone.
The primary endpoint of the trial will be to determine whether a greater
proportion of patients in the arm treated with OGX-011 and
docetaxel/prednisone experiences durable pain palliation as compared to
patients in the arm treated with docetaxel/prednisone alone. It is expected
that approximately 50 clinical sites in the United States and Canada will
participate in this trial.
"Patients with pain due to metastatic prostate cancer generally require
narcotic medications that are dosed to provide maximum pain relief; however,
unacceptable side effects such as sedation and severe constipation remain
dose-limiting. Because of this, patients frequently continue to suffer from
pain despite 'optimally dosed' narcotics," said Cindy Jacobs, M.D., Ph.D.,
OncoGenex' Executive Vice-President and Chief Medical Officer. "Thus, pain is
a common, often unremitting and disabling symptom of advanced prostate cancer,
and pain control is a key measurement of clinical benefit."
The planned initiation of this Phase 3 trial evaluating pain palliation
is supported by encouraging Phase 2 data from patients receiving OGX-011 plus
docetaxel as second-line chemotherapy - additional data was presented at the
2009 Annual Meeting of the American Urological Association (AUA). Based on the
27 patients who had prostate cancer-related pain and received OGX-011 plus
docetaxel as second-line chemotherapy, 12 patients or 44% of patients,
experienced pain palliation for 3 months or longer. The majority of pain
responses occurred within the first two cycles of OGX-011 plus docetaxel.
These data compare favorably even when compared to pain responses observed
after first-line chemotherapy. This is clinically relevant because patients
receiving second-line treatment have more advanced disease and are thought to
have more profound or resistant prostate cancer-related pain.
OGX-011 is designed to inhibit the production of clusterin, a protein
that is associated with cancer treatment resistance and is currently being
evaluated in Phase 2 clinical trials in prostate, lung and breast cancer.
OncoGenex Pharmaceuticals announced preliminary data on December 3, 2008 that
OGX-011 showed an overall survival advantage in a randomized, controlled Phase
2 trial in first-line treatment of metastatic castrate resistant prostate
cancer, in which the median survival for patients receiving OGX-011 in
combination with docetaxel and prednisone was 27.5 months, compared to 16.9
months in patients receiving docetaxel and prednisone alone. Updated survival
results will be presented at the 2009 Annual Meeting of the American Society
of Clinical Oncology.
At the 2008 Annual Meeting of the American Society of Clinical Oncology,
OncoGenex reported Phase 2 data with OGX-011 in combination with second-line
treatment of metastatic castrate resistant prostate cancer showing better than
expected survival results, reductions in levels of clusterin, durable
reductions in pain, and a decline in PSA, a protein that is often elevated in
patients with prostate cancer.
Based on clinical results to date, OncoGenex intends to conduct Phase 3
registration trials with OGX-011 in metastatic castrate resistant prostate
cancer, subject to the receipt of additional funding. The U.S. Food & Drug
Administration (FDA) has currently agreed on the design of two Phase 3
registration trials, via the Special Protocol Assessment (SPA) process, of
OGX-011 in combination with second-line chemotherapy. One trial design
investigates overall survival as the primary endpoint; the other trial design
investigates pain palliation as the primary endpoint. OGX-011 has received
Fast Track designation from the FDA for the treatment of progressive
metastatic prostate cancer in combination with docetaxel.
OncoGenex holds an exclusive license for patents related to clusterin
inhibition obtained from the University of British Columbia based on
discoveries made by researchers at the Prostate Centre at Vancouver General
Hospital. OGX-011 utilizes second-generation antisense technology, licensed
from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit
production of clusterin protein in tumor cells. OncoGenex and Isis partnered
in the successful discovery and initial development of OGX-011 and, in 2008,
amended their agreement to provide OncoGenex with sole rights to OGX-011 and
sole responsibility for development costs and partnering decisions, subject to
financial obligations to Isis.
About the Special Protocol Assessment and Agreement Process
Under a Special Protocol Assessment (SPA), a company and the FDA can
reach an agreement on the design and size of a clinical trial to support a
regulatory submission. This agreement can be in writing and cannot be changed
after the clinical trial begins except: (i) with written agreement of the
company and the FDA; or (ii) if the director of the FDA reviewing division
determines that "a substantial scientific issue essential to determining the
safety or effectiveness of the drug" was identified after testing began.
About OncoGenex Pharmaceuticals
OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the
development and commercialization of new therapies that address unmet needs in
the treatment of cancer. OncoGenex has a deep oncology pipeline, with each
product candidate having a distinct mechanism of action and representing a
unique opportunity for cancer drug development. OGX-011, the lead candidate
currently completing five Phase 2 clinical studies in prostate, lung and
breast cancers, is designed to inhibit the production of a specific protein
associated with treatment resistance; OGX-427 is in Phase 1 clinical
development; SN2310 has completed enrollment in a Phase 1 clinical trial; and
CSP-9222 and OGX-225 are currently in pre-clinical development. More
information is available at www.oncogenex.com.
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995, including statements concerning the potential survival benefit of
OGX-011, anticipated clinical development activities, timing of these
activities, the ability of future trials to demonstrate clinical benefit and
the potential for regulatory approvals. All statements other than statements
of historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current expectations
and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those
described in the forward-looking statements.
The potential risks and uncertainties associated with forward-looking
statements include, among others, the possibility that any benefit in patient
survival will not be maintained or will become less substantial as patient
survival follow up continues, risks that clinical trials will not be
successful or confirm earlier clinical trial results, including the risk that
the survival benefit will not be confirmed by a Phase 3 clinical trial, risks
associated with obtaining funding from third parties or completing a financing
necessary to support the costs and expenses of a Phase 3 clinical trial, the
timing and costs of clinical trials and regulatory approvals will be different
than management currently anticipates, risks relating to the development,
safety and efficacy of therapeutic drugs and potential applications for these
products and the risk factors set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K
for fiscal year 2008 and. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof.
For further information:
For further information: OncoGenex Contact: Scott Cormack, President &
CEO, (604) 736-3678, email@example.com; Media and Investor Contact: Jason
Spark, Porter Novelli Life Sciences, (619) 849-6005,